TransMedics Group (NASDAQ:TMDX) Shares Up 5.9% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX) shares rose 5.9% on Friday . The company traded as high as $143.30 and last traded at $142.55. Approximately 627,862 shares were traded during trading, a decline of 19% from the average daily volume of 776,607 shares. The stock had previously closed at $134.57.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TMDX shares. Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. raised their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday. Morgan Stanley boosted their price target on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $150.67.

TransMedics Group Price Performance

The firm has a market cap of $4.98 billion, a PE ratio of 29.64 and a beta of 2.06. The firm’s fifty day simple moving average is $133.80 and its two-hundred day simple moving average is $126.41. The company has a quick ratio of 7.13, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Royal Bank of Canada raised its position in shares of TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after buying an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after acquiring an additional 868 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after acquiring an additional 86,721 shares in the last quarter. AlphaQuest LLC increased its holdings in TransMedics Group by 51.4% in the 2nd quarter. AlphaQuest LLC now owns 1,950 shares of the company’s stock valued at $261,000 after acquiring an additional 662 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in TransMedics Group by 12.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 26,298 shares of the company’s stock worth $3,524,000 after purchasing an additional 2,933 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.